{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:55:11Z","timestamp":1793228111228,"version":"4.5.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,23]]},"abstract":"<jats:p>\n                    This study aims to evaluate the clinical efficacy and safety of different subcutaneous injection methods for the combined administration of pertuzumab and trastuzumab in patients with HER2-positive breast cancer through a retrospective analysis. This retrospective study reviewed the clinical records of 94 female patients with HER2-positive breast cancer who received combined subcutaneous injections of pertuzumab and trastuzumab at the Affiliated Hospital of Southwest Medical University (Luzhou, China) between January 2024 and March 2025. According to the injection method recorded in medical charts, patients were divided into 2 groups: the experimental group (slow bolus injection using an infusion pump) and the control group (traditional manual slow bolus injection by nurses). Clinical data were collected and compared between the 2 groups, focusing on postinjection local adverse reactions, including pain, subcutaneous bleeding, induration, and swelling. The incidence rates of postinjection pain, swelling, induration, and subcutaneous bleeding were significantly lower in the infusion pump group than in the manually injected group (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.05). No severe local reactions were observed in either group. This retrospective analysis suggests that using a slow bolus injection with an infusion pump may reduce local adverse reactions following subcutaneous administration of pertuzumab and trastuzumab in patients with HER2-positive breast cancer. The standardized use of infusion pumps could enhance patient comfort, safety, and overall treatment experience.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000046884","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T18:00:27Z","timestamp":1769191227000},"page":"e46884","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Reducing treatment burden in HER2+ breast cancer: Evaluating subcutaneous injection methods for pertuzumab\/trastuzumab combination therapy"],"prefix":"10.1097","volume":"105","author":[{"given":"Ruchun","family":"Zheng","sequence":"first","affiliation":[{"name":"Medical Aesthetic Center, Southwest Medical University Affiliated Hospital, Luzhou, Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghao","family":"Liang","sequence":"additional","affiliation":[{"name":"Southwest Medical University Affiliated Hospital, Luzhou, Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Southwest Medical University Affiliated Hospital, Luzhou, Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianlan","family":"Liu","sequence":"additional","affiliation":[{"name":"Breast Surgery Department, Southwest Medical University Affiliated Hospital, Luzhou, Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simin","family":"Yuan","sequence":"additional","affiliation":[{"name":"Southwest Medical University Affiliated Hospital, Luzhou, Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shizhen","family":"Li","sequence":"additional","affiliation":[{"name":"Breast Surgery Department, Southwest Medical University Affiliated Hospital, Luzhou, Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9782-4739","authenticated-orcid":false,"given":"Xirun","family":"Liu","sequence":"additional","affiliation":[{"name":"Clinical Trial Center of Southwest Medical University Affiliated Hospital, Luzhou, Sichuan Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260610","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","article-title":"Breast cancer: pathogenesis and treatments.","volume":"10","author":"Xiong","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"R2-20260610","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s44178-022-00007-8","article-title":"CACA guidelines for holistic integrative management of breast cancer.","volume":"1","author":"Wu","year":"2022","journal-title":"Holist Integr Oncol"},{"key":"R3-20260610","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.3390\/cancers12082081","article-title":"The changing paradigm for the treatment of HER2-positive breast cancer.","volume":"12","author":"Patel","year":"2020","journal-title":"Cancers (Basel)"},{"key":"R4-20260610","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1016\/S0140-6736(16)32417-5","article-title":"HER2-positive breast cancer.","volume":"389","author":"Loibl","year":"2017","journal-title":"Lancet"},{"key":"R5-20260610","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1703643","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer.","volume":"377","author":"von Minckwitz","year":"2017","journal-title":"N Engl J Med"},{"key":"R6-20260610","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S1470-2045(20)30536-2","article-title":"Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.","volume":"22","author":"Tan","year":"2021","journal-title":"Lancet Oncol"},{"key":"R7-20260610","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ejca.2021.03.047","article-title":"Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): a randomised, open-label phase II study.","volume":"152","author":"O\u2019Shaughnessy","year":"2021","journal-title":"Eur J Cancer"},{"key":"R8-20260610","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ejca.2017.05.009","article-title":"Patients\u2019 preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: results of the randomised MetaspHer study.","volume":"82","author":"Pivot","year":"2017","journal-title":"Eur J Cancer"},{"key":"R9-20260610","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S1470-2045(13)70383-8","article-title":"Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study.","volume":"14","author":"Pivot","year":"2013","journal-title":"Lancet Oncol"},{"key":"R10-20260610","doi-asserted-by":"crossref","first-page":"e007667","DOI":"10.1136\/jitc-2023-007667","article-title":"Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer-Immun-HER trial (GOIRC-01-2016).","volume":"11","author":"Pellegrino","year":"2023","journal-title":"J ImmunoTher Cancer"},{"key":"R11-20260610","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s41669-022-00361-3","article-title":"A systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting.","volume":"7","author":"McCloskey","year":"2023","journal-title":"PharmacoEcon Open"},{"key":"R12-20260610","doi-asserted-by":"crossref","first-page":"1338546","DOI":"10.3389\/fphar.2024.1338546","article-title":"The burden of systemic therapy administration route in treating HER2-positive breast cancer (for patients, healthcare professionals, and healthcare system): a systematic literature review.","volume":"15","author":"Landeiro","year":"2024","journal-title":"Front Pharmacol"},{"key":"R13-20260610","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/S0140-6736(20)32381-3","article-title":"Breast cancer.","volume":"397","author":"Loibl","year":"2021","journal-title":"Lancet"},{"key":"R14-20260610","first-page":"477","article-title":"Breast cancer statistics 2024.","volume":"74","author":"Giaquinto","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R15-20260610","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/cac2.12358","article-title":"Breast cancer: an up-to-date review and future perspectives.","volume":"42","author":"Hong","year":"2022","journal-title":"Cancer Commun (Lond)"},{"key":"R16-20260610","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1200\/JCO.1998.16.4.1340","article-title":"neu\/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group.","volume":"16","author":"Andrulis","year":"1998","journal-title":"J Clin Oncol"},{"key":"R17-20260610","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S1470-2045(16)00163-7","article-title":"5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.","volume":"17","author":"Gianni","year":"2016","journal-title":"Lancet Oncol"},{"key":"R18-20260610","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s40264-014-0232-1","article-title":"Benefits and risks of using smart pumps to reduce medication error rates: a systematic review.","volume":"37","author":"Ohashi","year":"2014","journal-title":"Drug Saf"},{"key":"R19-20260610","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1046\/j.1525-1403.2002.02026.x","article-title":"Operating principles and clinical implications of constant flow pumps.","volume":"5","author":"Cameron","year":"2002","journal-title":"Neuromodulation"},{"key":"R20-20260610","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1007\/s00125-022-05864-6","article-title":"Congenital malformations among offspring of women with type 1 diabetes who use insulin pumps: a prospective cohort study.","volume":"66","author":"Thorius","year":"2023","journal-title":"Diabetologia"},{"key":"R21-20260610","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s40264-015-0308-6","article-title":"Accidents and incidents related to intravenous drug administration: a pre-post study following implementation of smart pumps in a teaching hospital.","volume":"38","author":"Gu\u00e9rin","year":"2015","journal-title":"Drug Saf"},{"key":"R22-20260610","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/ajhp\/61.2.177","article-title":"Preventing medication errors with smart infusion technology.","volume":"61","author":"Wilson","year":"2004","journal-title":"Am J Health Syst Pharm"},{"key":"R23-20260610","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jen.2010.07.006","article-title":"Use of intravenous smart pumps for patient safety.","volume":"37","author":"Harding","year":"2011","journal-title":"J Emerg Nurs"},{"key":"R24-20260610","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/00129804-200509000-00005","article-title":"Intravenous medication safety and smart infusion systems: lessons learned and future opportunities.","volume":"28","author":"Keohane","year":"2005","journal-title":"J Infus Nurs"},{"key":"R25-20260610","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/01.NAJ.0000410360.20567.55","article-title":"Increasing the use of \u201csmart\u201d pump drug libraries by nurses: a continuous quality improvement project.","volume":"112","author":"Harding","year":"2012","journal-title":"Am J Nurs"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046884","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T10:00:45Z","timestamp":1781085645000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000046884","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"2025-10-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}